EIF2A and acute myeloid leukemia: A previous research work reported that the activation of mTORC1 signaling promotes the proliferation and survival of the leukemic clones (Steelman et al., 2008; Park et al., 2010) and cytotoxicity in AML cells from the selective AMPK agonist (GSK621) because of mTORC1 activation which was through the eIF2α/ATF4 signaling pathway (Sujobert et al., 2015).